Highlights

  • SomnoMed develops custom oral appliances for obstructive sleep apnoea patients seeking alternatives to traditional treatments.
  • FY26 results showed improving profitability with EBITDA growth exceeding Revenue growth.
  • The company launched Virtus to expand its sleep apnoea and bruxism treatment offering.
  • Future performance depends on North American growth, product adoption and continued Margin improvement.

SomnoMed (ASX:SOM) develops custom oral appliances for obstructive sleep apnoea, providing dental-style devices designed to help keep airways open during sleep. The company operates within the global sleep-disorder market, offering an alternative treatment option for patients who may not prefer traditional therapies.

With improving margins, growth in its key North American market and the introduction of a new product, SomnoMed continues attracting attention from healthcare investors assessing its next phase of expansion.

Recent Development

For FY26, SomnoMed (ASX:SOM) reported revenue growth of 3% to A$114.5 million, while EBITDA increased 19% to A$10.9 million. The EBITDA margin improved to 9.6% from 8.2% in the previous year.

North America remained the company’s largest market, contributing A$45.8 million in revenue, representing growth of 6% on a reported basis and 11% in constant currency terms.

During FY26, SomnoMed launched Virtus, a device designed for patients experiencing both sleep apnoea and bruxism. The product entered a controlled market release phase.

The company also transitioned to a single CEO structure under Karen Borg following Amrita Blickstead stepping down as Co-CEO. Greg Knight was appointed COO and Nathan Minnich was appointed CMO.

Financial Performance

SomnoMed’s (ASX:SOM) FY26 performance highlighted improving operating leverage, with EBITDA growth significantly exceeding revenue growth.

The increase in EBITDA margin from 8.2% to 9.6% indicates improved cost management and stronger profitability from the existing revenue base.

North America remains a key contributor due to its scale and continued growth momentum. The region’s constant-currency growth rate highlights its importance within the company’s expansion strategy.

The Virtus product launch provides an opportunity to broaden SomnoMed’s addressable market by targeting patients with both sleep apnoea and bruxism. However, wider commercial adoption remains an important Factor to monitor as the product moves beyond its initial release stage.

What Could Drive the Shares Next?

The key drivers for SomnoMed (ASX:SOM) include continued growth in North America, broader adoption of Virtus and further improvement in operating margins.

Successful expansion of new products that can lift revenue growth beyond the low-single-digit pace recorded in FY26 would be an important milestone.

Stability following the Leadership transition and continued growth through dental and sleep-clinic channels could also influence the company’s future performance.

Key Risks

SomnoMed (ASX:SOM) continues operating in a competitive sleep-treatment market, with alternative therapies such as CPAP remaining widely used.

Revenue growth was relatively modest in FY26, meaning future performance depends on new products, market expansion and continued margin improvements.

Adoption of Virtus at scale remains unproven, while changes in leadership may introduce execution risks during the company’s next growth phase.

Investor Outlook

SomnoMed (ASX:SOM) delivered a FY26 result that combined modest revenue growth with stronger profitability, improved margins and the introduction of a new product opportunity.

The company’s future progress will depend on maintaining North American momentum, successfully expanding Virtus adoption and continuing to improve operational efficiency.

Future updates on revenue growth, EBITDA margins and product uptake will be important indicators of whether SomnoMed can build on its recent progress.